Open AccessExpert consensus on image‐guided radiofrequency ablation of pulmonary tumors: 2018 edition
Author(s) -
Liu BaoDong,
Ye Xin,
Fan WeiJun,
Li XiaoGuang,
Feng WeiJian,
Lu Qiang,
Mao Yu,
Lin ZhengYu,
Li Lu,
Zhuang YiPing,
Ni XuDong,
Shen JiaLin,
Fu YiLi,
Han JianJun,
Li ChenRui,
Liu Chen,
Yang WuWei,
Su ZhiYong,
Wu ZhiYuan,
Liu Lei
Publication year - 2018
Publication title -
thoracic cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.823
H-Index - 28
eISSN - 1759-7714
pISSN - 1759-7706
DOI - 10.1111/1759-7714.12817
Subject(s) - medicine , radiofrequency ablation , percutaneous , ablation , radiology , lung cancer , clinical trial , surgery , radiation therapy , oncology
Lung cancer ranks first in incidence and mortality in China. Surgery is the primary method to cure cancer, but only 20–30% of patients are eligible for curative resection. In recent years, in addition to surgery, other local therapies have been developed for patients with numerous localized primary and metastatic pulmonary tumors, including stereotactic body radiation therapy and thermal ablative therapies through percutaneously inserted applicators. Percutaneous thermal ablation of pulmonary tumors is minimally invasive, conformal, repeatable, feasible, cheap, has a shorter recovery time, and offers reduced morbidity and mortality. Radiofrequency ablation (RFA), the most commonly used thermal ablation technique, has a reported 80–90% rate of complete ablation, with the best results obtained in tumors < 3 cm in diameter. Because the clinical efficacy of RFA of pulmonary tumors has not yet been determined, this clinical guideline describes the techniques used in the treatment of localized primary and metastatic pulmonary tumors in nonsurgical candidates, including mechanism of action, devices, indications, techniques, potential complications, clinical outcomes, post‐ablation surveillance, and use in combination with other therapies. In the future, the role of RFA in the treatment of localized pulmonary tumors should ultimately be determined by evidence from prospective randomized controlled trials comparing sublobar resection or stereotactic body radiation therapy.